According to the findings of recent studies, treatment with SGLT2 inhibitors plus insulin is a suitable regimen for patients with T2D, especially those requiring a high insulin dose daily and those with insulin resistance, obesity, or high risks of cardiovascular disease. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.